-+ 0.00%
-+ 0.00%
-+ 0.00%

IGC Pharma Adds Integrative Clinical Trials Site In Brooklyn

Benzinga·01/22/2026 14:04:51
Listen to the news

IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today announced the addition of Integrative Clinical Trials, LLC, located in Brooklyn, New York, as a new clinical site participating in the Company's Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease.

Integrative Clinical Trials is a clinical research center conducting studies across a broad range of Central Nervous System ("CNS") disorders, including Alzheimer's disease and mild cognitive impairment. The site is led by Dr. Inna Yuryev-Golger, MD, who serves as Principal Investigator and brings more than 10 years of experience conducting clinical research. Bella Yevseva serves as the Clinical Trial Coordinator.